75N94022Q00117_NanoView_Features_Doc.pdf

PDF 77 KB Posted

Attached to
ExoView R200 Imaging Platform Federal contract opportunity
Solicitation number
75N94022Q00117
Issued by
Department of Health and Human Services National Institutes of Health National Institute of Child Health and Human Development

View the file

Other files for this federal contract opportunity

Other files attached to ExoView R200 Imaging Platform, newest first.
File Type Posted
75N94022Q00117_NanoView_Biosciences.pdf PDF

On GovTribe

Work with this file on GovTribe

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

The ExoView R200 is a unique, automated platform for the multi-level characterization of extracellular vesicles.

The technology is unique in its operation and many of the features and benefits of the technology are not available in other commercially available characterization tools.

Unique features include:

• 4 excitation sources to permit the colocalization of EV markers at the single EV level.

• The ability to measure relative fluorescence intensity at the single EV level, therefore providing the ability to measure relative biomarker expression.

• Automatic measurement of up to 16 samples with R200 microscope reader.

• Affinity-based capture and detection of EVs that does not require pre-purification of sample. Cell culture supernatant, plasma, serum, urine, saliva and other biological fluids have been tested and can be directly measured without the need for sample purification.

• The ability to detect rare events down to 6exp6 EVs per ml.

• The ability to measure specific EV subpopulations with a concentration of less than 0.5% of the overall EV population.

• The ability to measure up to 5 biomarkers per single EV.

• The ability to measure with single-copy sensitivity, protein biomarkers on individual EVs

• A validated protocol for the measurement of EV cargo proteins at the single EV level.

• Customizable EV assays for the specific detection of specific EV subpopulations

• The ability to highly plex the capture of EVs across a panel of up to 8 specific capture antibodies for rapid screening of EV biomarker candidates.

• Validated protocols for the detection and quantification of EVs expressing ubiquitous tetraspanin markers (CD9, CD63, CD81)

File details come from the government source that posted it. Updated .